GlassScriptPhysician profile
Kalyanam Subramanyam
NPI 1164493870
$6,412.70
in general payments reported to CMS, 2019-2025
26 companies · $580 in 2025
The $580 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $694 · 2021: $1,067 · 2022: $794 · 2023: $1,173 · 2024: $1,442 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,617.96 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,267.32 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $955.75 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.03 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Pfizer INC. | $420.96 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $349.87 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $302.92 | 2020-2024 | Dificid |
| Lilly USA, LLC | $145.75 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $132.53 | 2020-2022 | |
| Celgene Corporation | $98.29 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $90.56 | 2020-2024 | |
| Janssen Biotech, INC. | $88.76 | 2019-2023 | Simponi, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $84.06 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $71.43 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $59.05 | 2020-2024 | Sutab, Suflave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $40.61 | 2020 | |
| Evoke Pharma, INC. | $39.29 | 2023 | Gimoti |
| Madrigal Pharmaceuticals | $34.80 | 2025 | Rezdiffra |
| Ardelyx, INC. | $27.31 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.97 | 2024 | Cyltezo |
| Boston Scientific Corporation | $21.35 | 2023 | Captivator II |
| Celltrion USA INC. | $18.40 | 2025 | Vegzelma |
| Qol Medical, LLC | $15.86 | 2019 | |
| Exact Sciences Corporation | $15.47 | 2023 | Cologuard Collection Kit |
| Pentax of America, INC. | $14.49 | 2020 | |
| Allergan, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalyanam Subramanyam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.